[1] McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS microbiology reviews. 2013;37(2):130-55.
[2] Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 2008;21(3):538-82.
[3] Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M, Tilahun M, Bisetegn H, Sahle Z, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infection and drug resistance. 2021:3711-9.
[4] Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021;10(3):373.
[5] Nowak P, Paluchowska P. Acinetobacter baumannii: biology and drug resistance—role of carbapenemases. Folia histochemica et cytobiologica. 2016;54(2):61-74.
[6] Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G, Álvarez-Hernández DA, Moncaleano Guzmán V, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205.
[7] Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature. Osong public health and research perspectives. 2015;6(2):79-86.
[8] Keikha M, Karbalaei M, Rahimi F, Abadi AT. The prevalence of antibiotic-resistant Acinetobacter baumannii infections among the Iranian ICU patients: A systematic review and meta-analysis. Gene Reports. 2023;30:101731.
[9] Rahimzadeh G, Rezai MS, Farshidi F. Genotypic patterns of multidrug-resistant Acinetobacter baumannii: A systematic review. Advanced Biomedical Research. 2023;12(1):56.
[10] Cain AK, Hamidian M. Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii. PLoS Pathogens. 2023;19(8):e1011520.
[11] Wu HJ, Xiao ZG, Lv XJ, Huang HT, Liao C, Hui CY, Xu Y, Li HF, et al. Drug‑resistant Acinetobacterábaumannii: From molecular mechanisms to potential therapeutics. Experimental and therapeutic medicine. 2023;25(5):1-0.
[12] Tavasol A, Khademolhosseini S, Noormohamad M, Ghasemi M, Mahram H, Salimi M, Fathi M, Sardaripour A, Zangi M, et al. Worldwide Prevalence of Carbapenem Resistance in Acinetobacter baumannii: A Systematic Review and Meta-analysis. Infectious Diseases in Clinical Practice. 2023;31(2):e1236.
[13] Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3(3):243-50.
[14] Novović K, Jovčić B. Colistin resistance in Acinetobacter baumannii: molecular mechanisms and epidemiology. Antibiotics. 2023;12(3):516.
[15] Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, Karimaei S, Safari H, Azimi T, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microbial pathogenesis. 2020;139:103887.
[16] Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, Byun MK, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei medical journal. 2012;53(5):974.
[17] Keikha M, Kamali H, Ghazvini K, Karbalaei M. Conceptual framework of antibiotic stewardship programs in reducing ESBL-producing Enterobacteriaceae: a systematic review and meta-analysis. Journal of Chemotherapy. 2022;34(8):483-91.
[18] Humphries RM, Kircher S, Ferrell A, Krause KM, Malherbe R, Hsiung A, Burnham CA, et al. The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: report from the clinical and laboratory standards institute methods development and standardization working group. Journal of clinical microbiology. 2018;56(8):10-128.
[19] Azimi L, Talebi M, Pourshafie MR, Owlia P, Lari AR. Characterization of carbapenemases in extensively drug resistance Acinetobacter baumannii in a burn care center in Iran. International journal of molecular and cellular medicine. 2015;4(1):46.
[20] Ibrahim S, Al-Saryi N, Al-Kadmy IM, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Molecular biology reports. 2021;48(10):6987-98.
[21] Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, Muleiro Álvarez M, Vega López EN, Franyuti-Kelly G, Álvarez-Hernández DA, Moncaleano Guzmán V, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics. 2020;9(4):205.
[22] Rodriguez CH, Brune A, Nastro M, Vay C, Famiglietti A. In vitro synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant Acinetobacter baumannii. Journal of Medical Microbiology. 2020;69(7):928-31.
[23] Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. Journal of Chemotherapy. 2020;33(1):1-1.
[24] Karbasizade V, Heidari L. Antimicrobial resistance of Acinetobacter baumannii isolated from Intensive Care Units of Isfahan hospitals, Iran. Journal of Isfahan Medical School. 2012;30(191).
[25] Zahra N, Zeshan B, Qadri MM, Ishaq M, Afzal M, Ahmed N, et al. Phenotypic and genotypic evaluation of antibiotic resistance of Acinetobacter baumannii bacteria isolated from surgical intensive care unit patients in Pakistan. Jundishapur Journal of Microbiology. 2021;14(4).
[26] Şimşek M, Demir C. Determination of colistin and tigecycline resistance profile of Acinetobacter baumannii strains from different clinical samples in a territory hospital in Turkey. 2020.
[27] Lemos EV, de La Hoz FP, Einarson TR, McGhan WF, Quevedo E, Castañeda C, Kawai K, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clinical Microbiology and Infection. 2014;20(5):416-23.
[28] Lima WG, Alves GC, Sanches C, Fernandes SO, de Paiva MC. Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: A systematic review and meta-analysis. Burns. 2019;45(7):1495-508.
[29] Beigverdi R, Sattari-Maraji A, Emaneini M, Jabalameli F. Status of carbapenem-resistant Acinetobacter baumannii harboring carbapenemase: First systematic review and meta-analysis from Iran. Infection, Genetics and Evolution. 2019;73:433-43.
[30] Hashemizadeh Z, Emami A, Rahimi MJ. Acinetobacter antibiotic resistance and frequency of ESBL-producing strains in ICU patients of Namazi Hospital (2008-2009). Journal of Inflammatory Diseases. 2010;14(2):47-53.
[31] Japoni-Nejad A, Sofian M, van Belkum A, Ghaznavi-Rad E. Nosocomial outbreak of extensively and pan drug-resistant Acinetobacter baumannii in tertiary hospital in central part of Iran. Jundishapur Journal of microbiology. 2013;6(8).
[32] Karbalaei M, Keikha M. Antimicrobial stewardship for surgeons; the urgent need for new directions–Correspondence. International Journal of Surgery. 2022;104:106758.
[33] Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E, Navidifar T, Darban-Sarokhalil D, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2024;13(1):24.
[34] Pormohammad A, Mehdinejadiani K, Gholizadeh P, Nasiri MJ, Mohtavinejad N, Dadashi M, Karimaei S, Safari H, Azimi T, et al. Global prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: A systematic review and meta-analysis. Microbial pathogenesis. 2020;139:103887.
[35] Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E, Navidifar T, Darban-Sarokhalil D, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2024;13(1):24.
)